WA
VRTX icon

WPG Advisers’s Vertex Pharmaceuticals VRTX Stock Holding History

WPG Advisers’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$133K Buy
268
+16
+6% +$7.09K 0.08% 154
2026
Q1 		$113K Buy
252
+7
+3% +$3.26K 0.08% 132
2025
Q4 		$111K Buy
245
+9
+4% +$3.88K 0.08% 152
2025
Q3 		$92.4K Sell
236
-57
-19% -$23.8K 0.07% 177
2025
Q2 		$130K Sell
293
-3
-1% -$1.38K 0.11% 123
2025
Q1 		$144K Buy
296
+2
+0.7% +$932 0.13% 115
2024
Q4 		$118K Buy
+294
New +$136K 0.11% 160

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

WPG Advisers's VRTX Position: Q2 2026 in Review

WPG Advisers increased its Vertex Pharmaceuticals (VRTX) stake by 6.3% in Q2 2026, buying an estimated $7.09K and bringing the position to 268 shares worth $133K. The position accounts for 0.08% of the portfolio, ranked #154.

WPG Advisers first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $144K in Q1 2025. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • WPG Advisers held 268 shares of Vertex Pharmaceuticals worth $133K as of Q2 2026.
  • WPG Advisers bought 16 Vertex Pharmaceuticals shares in Q2 2026, an estimated $7.09K.
  • Vertex Pharmaceuticals made up 0.08% of WPG Advisers's portfolio in Q2 2026, its #154 holding.
  • WPG Advisers first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • WPG Advisers's Vertex Pharmaceuticals position peaked at $144K in Q1 2025.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on WPG Advisers's 13F filing for Q2 2026, filed 6 Aug 2026.